Important Information

This website is managed by Ultima Markets’ international entities, and it’s important to emphasise that they are not subject to regulation by the FCA in the UK. Therefore, you must understand that you will not have the FCA’s protection when investing through this website – for example:

  • You will not be guaranteed Negative Balance Protection
  • You will not be protected by FCA’s leverage restrictions
  • You will not have the right to settle disputes via the Financial Ombudsman Service (FOS)
  • You will not be protected by Financial Services Compensation Scheme (FSCS)
  • Any monies deposited will not be afforded the protection required under the FCA Client Assets Sourcebook. The level of protection for your funds will be determined by the regulations of the relevant local regulator.

Note: Ultima Markets is currently developing a dedicated website for UK clients and expects to onboard UK clients under FCA regulations in 2026.

If you would like to proceed and visit this website, you acknowledge and confirm the following:

  • 1.The website is owned by Ultima Markets’ international entities and not by Ultima Markets UK Ltd, which is regulated by the FCA.
  • 2.Ultima Markets Limited, or any of the Ultima Markets international entities, are neither based in the UK nor licensed by the FCA.
  • 3.You are accessing the website at your own initiative and have not been solicited by Ultima Markets Limited in any way.
  • 4.Investing through this website does not grant you the protections provided by the FCA.
  • 5.Should you choose to invest through this website or with any of the international Ultima Markets entities, you will be subject to the rules and regulations of the relevant international regulatory authorities, not the FCA.

Ultima Markets wants to make it clear that we are duly licensed and authorised to offer the services and financial derivative products listed on our website. Individuals accessing this website and registering a trading account do so entirely of their own volition and without prior solicitation.

By confirming your decision to proceed with entering the website, you hereby affirm that this decision was solely initiated by you, and no solicitation has been made by any Ultima Markets entity.

I confirm my intention to proceed and enter this website

Tag Archives: 歐洲

當投資人搜尋更多政策線索時,歐洲股市於近4個月高位飛翔  

投資者在上週大漲後稍作喘息,歐洲股市週一表現平淡,Stoxx 50 指數和Stoxx 600 指數等主要股指徘徊在四個月高點附近。 最近的飆升是由於人們對央行可能很快展開降息的樂觀情緒加溫。 在週一市場中,零售商和銀行小幅上漲,而礦業和能源股則下跌 1-2%。  從企業消息來看,瑞士製藥巨頭羅氏(Roche)已達成協議,以 27 億美元首期付款收購 Carmot Therapeutics,這是一家專注於開發減重藥物的私人公司。 此舉使羅氏成為領先減肥藥物製造商諾和諾德(Novo Nordisk)和禮來(Eli Lilly)公司的競爭對手。  同時,英瑞製藥商阿斯特捷利康 (AstraZeneca) 宣佈與美國專注於人工智慧的生物技術公司 Absci 建立合作夥伴關係。 該合作協議價值高達 2.47 億美元,意旨在利用 Absci 的 AI 藥物創造平台設計一種用於治療多種癌症的新抗體。  隨著本週的進展,投資者將密切關注週五的美國非農就業數據,尋求有關聯準會未來政策路徑的線索。 分析師普遍預期聯準會將在 2023 年放緩升息步伐,但勞動市場的強勁程度仍是一個懸而未決的問題。  (EURO STOXX 50,半年線圖)  免責聲明  本文所含評論、新聞、研究、分析、價格及其他資料只能視作一般市場資訊,僅為協助讀者瞭解市場形勢而提供,並不構成投資建議。Ultima Markets已採取合理措施確保資料的準確性,但不能保證資料的精確度,及可隨時更改而毋須作出通知。Ultima Markets不會為直接或間接使用或依賴此等資料而可能引致的任何虧損或損失(包括但不限於任何盈利的損失)負責。